

# Anirban Maitra

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1400747/publications.pdf>

Version: 2024-02-01

228  
papers

43,353  
citations

6124

83  
h-index

2634

200  
g-index

241  
all docs

241  
docs citations

241  
times ranked

49448  
citing authors

#	ARTICLE	IF	CITATIONS
1	Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses. <i>Science</i> , 2008, 321, 1801-1806.	6.0	3,755
2	Genomic analyses identify molecular subtypes of pancreatic cancer. <i>Nature</i> , 2016, 531, 47-52.	13.7	2,700
3	Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. <i>Cancer Cell</i> , 2003, 4, 437-450.	7.7	2,150
4	Whole genomes redefine the mutational landscape of pancreatic cancer. <i>Nature</i> , 2015, 518, 495-501.	13.7	2,132
5	A draft map of the human proteome. <i>Nature</i> , 2014, 509, 575-581.	13.7	1,948
6	Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival. <i>Cancer Cell</i> , 2014, 25, 719-734.	7.7	1,892
7	EMT and Dissemination Precede Pancreatic Tumor Formation. <i>Cell</i> , 2012, 148, 349-361.	13.5	1,746
8	Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. <i>Nature</i> , 2012, 491, 399-405.	13.7	1,741
9	Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. <i>Science</i> , 2017, 357, 1156-1160.	6.0	1,059
10	Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. <i>Cell</i> , 2019, 178, 795-806.e12.	13.5	830
11	Recurrent <i>GNAS</i> Mutations Define an Unexpected Pathway for Pancreatic Cyst Development. <i>Science Translational Medicine</i> , 2011, 3, 92ra66.	5.8	703
12	Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism. <i>ELife</i> , 2016, 5, e10250.	2.8	681
13	Blockade of Hedgehog Signaling Inhibits Pancreatic Cancer Invasion and Metastases: A New Paradigm for Combination Therapy in Solid Cancers. <i>Cancer Research</i> , 2007, 67, 2187-2196.	0.4	647
14	Pancreatic Cancer. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2008, 3, 157-188.	9.6	634
15	Genomic alterations in cultured human embryonic stem cells. <i>Nature Genetics</i> , 2005, 37, 1099-1103.	9.4	592
16	Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 21188-21193.	3.3	585
17	Presence of Somatic Mutations in Most Early-Stage Pancreatic Intraepithelial Neoplasia. <i>Gastroenterology</i> , 2012, 142, 730-733.e9.	0.6	568
18	Early Detection of Pancreatic Cancer: Opportunities and Challenges. <i>Gastroenterology</i> , 2019, 156, 2024-2040.	0.6	476

#	ARTICLE	IF	CITATIONS
19	Pancreatic cancer stroma: an update on therapeutic targeting strategies. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 487-505.	8.2	458
20	Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 10202-10207.	3.3	438
21	The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. <i>Genes and Development</i> , 2010, 24, 2383-2388.	2.7	426
22	Genetics and biology of pancreatic ductal adenocarcinoma. <i>Genes and Development</i> , 2016, 30, 355-385.	2.7	416
23	An In vivo Platform for Translational Drug Development in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 4652-4661.	3.2	407
24	Pathology of Genetically Engineered Mouse Models of Pancreatic Exocrine Cancer: Consensus Report and Recommendations. <i>Cancer Research</i> , 2006, 66, 95-106.	0.4	401
25	Autophagy Is Critical for Pancreatic Tumor Growth and Progression in Tumors with p53 Alterations. <i>Cancer Discovery</i> , 2014, 4, 905-913.	7.7	395
26	Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. <i>Nature Communications</i> , 2015, 6, 7686.	5.8	393
27	Multicomponent Analysis of the Pancreatic Adenocarcinoma Progression Model Using a Pancreatic Intraepithelial Neoplasia Tissue Microarray. <i>Modern Pathology</i> , 2003, 16, 902-912.	2.9	363
28	Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 18913-18918.	3.3	358
29	Oncogenic Kras Activates a Hematopoietic-to-Epithelial IL-17 Signaling Axis in Preinvasive Pancreatic Neoplasia. <i>Cancer Cell</i> , 2014, 25, 621-637.	7.7	324
30	Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. <i>Journal of Pathology</i> , 2014, 233, 217-227.	2.1	308
31	Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 2541-2556.	0.8	302
32	DCLK1 Marks a Morphologically Distinct Subpopulation of Cells With Stem Cell Properties in Preinvasive Pancreatic Cancer. <i>Gastroenterology</i> , 2014, 146, 245-256.	0.6	277
33	Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer. <i>Gastroenterology</i> , 2019, 156, 108-118.e4.	0.6	270
34	Pancreatic cancer. <i>Current Problems in Cancer</i> , 2002, 26, 176-275.	1.0	268
35	Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression. <i>Clinical Cancer Research</i> , 2019, 25, 2194-2205.	3.2	268
36	Precursors to Invasive Pancreatic Cancer. <i>Advances in Anatomic Pathology</i> , 2005, 12, 81-91.	2.4	266

#	ARTICLE	IF	CITATIONS
37	Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. <i>American Journal of Surgical Pathology</i> , 2006, 30, 1067-76.	2.1	261
38	Early Detection of Sporadic Pancreatic Cancer. <i>Pancreas</i> , 2015, 44, 693-712.	0.5	255
39	Long Interspersed Element-1 Protein Expression Is a Hallmark of Many Human Cancers. <i>American Journal of Pathology</i> , 2014, 184, 1280-1286.	1.9	250
40	Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 3-8.	1.9	238
41	Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 1692-1697.	3.3	237
42	Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 375-403.	157.7	237
43	Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. <i>Gastroenterology</i> , 2019, 156, 2242-2253.e4.	0.6	224
44	Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	219
45	The Human MitoChip: A High-Throughput Sequencing Microarray for Mitochondrial Mutation Detection. <i>Genome Research</i> , 2004, 14, 812-819.	2.4	218
46	Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. <i>Nature</i> , 2017, 542, 119-123.	13.7	209
47	Increased Prevalence of Precursor Lesions in Familial Pancreatic Cancer Patients. <i>Clinical Cancer Research</i> , 2009, 15, 7737-7743.	3.2	195
48	Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. <i>Cancer Cell</i> , 2016, 29, 75-89.	7.7	191
49	Systemic Administration of Polymeric Nanoparticle-Encapsulated Curcumin (NanoCurc) Blocks Tumor Growth and Metastases in Preclinical Models of Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 2255-2264.	1.9	184
50	In vivo endomicroscopy improves detection of Barrett's esophagus-related neoplasia: a multicenter international randomized controlled trial (with video). <i>Gastrointestinal Endoscopy</i> , 2014, 79, 211-221.	0.5	183
51	Hypermutation In Pancreatic Cancer. <i>Gastroenterology</i> , 2017, 152, 68-74.e2.	0.6	174
52	Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution. <i>JCI Insight</i> , 2019, 4, .	2.3	169
53	Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes. <i>Annals of Oncology</i> , 2016, 27, 635-641.	0.6	166
54	Molecular pathogenesis of pancreatic cancer. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2006, 20, 211-226.	1.0	161

#	ARTICLE	IF	CITATIONS
55	Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2017, 35, 2324-2328.	0.8	160
56	Update on pancreatic intraepithelial neoplasia. <i>International Journal of Clinical and Experimental Pathology</i> , 2008, 1, 306-16.	0.5	159
57	Clinicopathological Correlates of Activating GNAS Mutations in Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas. <i>Annals of Surgical Oncology</i> , 2013, 20, 3802-3808.	0.7	158
58	Inhibiting the Cyclin-Dependent Kinase CDK5 Blocks Pancreatic Cancer Formation and Progression through the Suppression of Ras-Ral Signaling. <i>Cancer Research</i> , 2010, 70, 4460-4469.	0.4	140
59	Therapeutic Targeting of the Warburg Effect in Pancreatic Cancer Relies on an Absence of p53 Function. <i>Cancer Research</i> , 2015, 75, 3355-3364.	0.4	129
60	Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. <i>Nature</i> , 2019, 568, 410-414.	13.7	129
61	miR-181c Regulates the Mitochondrial Genome, Bioenergetics, and Propensity for Heart Failure In Vivo. <i>PLoS ONE</i> , 2014, 9, e96820.	1.1	128
62	Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. <i>Scientific Reports</i> , 2016, 6, 35848.	1.6	127
63	Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer. <i>Cancer Research</i> , 2018, 78, 246-255.	0.4	127
64	Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer. <i>Cancer Immunology Research</i> , 2017, 5, 182-190.	1.6	126
65	Immunohistochemical Validation of a Novel Epithelial and a Novel Stromal Marker of Pancreatic Ductal Adenocarcinoma Identified by Global Expression Microarrays. <i>American Journal of Clinical Pathology</i> , 2002, 118, 52-59.	0.4	124
66	Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 164-174.	0.9	124
67	Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity. <i>Nature Communications</i> , 2019, 10, 254.	5.8	120
68	Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenvironment. <i>Cancer Discovery</i> , 2020, 10, 608-625.	7.7	119
69	A Listeria Vaccine and Depletion of T-Regulatory Cells Activate Immunity Against Early Stage Pancreatic Intraepithelial Neoplasms and Prolong Survival of Mice. <i>Gastroenterology</i> , 2014, 146, 1784-1794.e6.	0.6	118
70	Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer. <i>Cancer Cell</i> , 2022, 40, 153-167.e11.	7.7	118
71	METTL13 Methylation of eEF1A Increases Translational Output to Promote Tumorigenesis. <i>Cell</i> , 2019, 176, 491-504.e21.	13.5	117
72	Quantitative imaging to evaluate malignant potential of IPMNs. <i>Oncotarget</i> , 2016, 7, 85776-85784.	0.8	115

#	ARTICLE	IF	CITATIONS
73	InÂvivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. <i>Cell Reports</i> , 2016, 16, 133-147.	2.9	114
74	Immune Cell Production of Interleukin 17 Induces Stem Cell Features of Pancreatic Intraepithelial Neoplasia Cells. <i>Gastroenterology</i> , 2018, 155, 210-223.e3.	0.6	114
75	Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma. <i>International Journal of Cancer</i> , 2013, 132, 785-794.	2.3	111
76	Tumour-reprogrammed stromal BCAT1 fuels branched-chain ketoacid dependency in stromal-rich PDAC tumours. <i>Nature Metabolism</i> , 2020, 2, 775-792.	5.1	110
77	Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2012, 9, 199-208.	8.2	106
78	Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. <i>Nature</i> , 2017, 542, 362-366.	13.7	105
79	Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma. <i>British Journal of Cancer</i> , 2020, 122, 498-505.	2.9	105
80	Loss of Stk11/Lkb1 Expression in Pancreatic and Biliary Neoplasms. <i>Modern Pathology</i> , 2003, 16, 686-691.	2.9	104
81	Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. <i>Cancer Biology and Therapy</i> , 2011, 12, 598-609.	1.5	103
82	Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts. <i>ELife</i> , 2019, 8, .	2.8	103
83	Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis. <i>Science</i> , 2021, 373, eabj0486.	6.0	99
84	Prrx1 isoform switching regulates pancreatic cancer invasion and metastatic colonization. <i>Genes and Development</i> , 2016, 30, 233-247.	2.7	97
85	Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. <i>Gastroenterology</i> , 2021, 160, 362-377.e13.	0.6	90
86	Translational advances in pancreatic ductal adenocarcinoma therapy. <i>Nature Cancer</i> , 2022, 3, 272-286.	5.7	90
87	Semaphorin 3D autocrine signaling mediates the metastatic role of annexin A2 in pancreatic cancer. <i>Science Signaling</i> , 2015, 8, ra77.	1.6	89
88	Very Long-term Survival Following Resection for Pancreatic Cancer Is Not Explained by Commonly Mutated Genes: Results of Whole-Exome Sequencing Analysis. <i>Clinical Cancer Research</i> , 2015, 21, 1944-1950.	3.2	85
89	Increased expression and processing of the Alzheimer amyloid precursor protein in pancreatic cancer may influence cellular proliferation. <i>Cancer Research</i> , 2003, 63, 7032-7.	0.4	85
90	Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. <i>JAMA Surgery</i> , 2017, 152, 1048.	2.2	82

#	ARTICLE	IF	CITATIONS
91	Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer. <i>Gastroenterology</i> , 2020, 159, 306-319.e12.	0.6	82
92	Evolution of cellular morpho-phenotypes in cancer metastasis. <i>Scientific Reports</i> , 2016, 5, 18437.	1.6	81
93	Simultaneous inhibition of hedgehog signaling and tumor proliferation remodels stroma and enhances pancreatic cancer therapy. <i>Biomaterials</i> , 2018, 159, 215-228.	5.7	81
94	A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2019, 111, 372-379.	3.0	79
95	HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. <i>Cell Reports</i> , 2020, 31, 107625.	2.9	78
96	Recent insights into the biology of pancreatic cancer. <i>EBioMedicine</i> , 2020, 53, 102655.	2.7	78
97	A Polymeric Nanoparticle Encapsulated Small-Molecule Inhibitor of Hedgehog Signaling (NanoHHI) Bypasses Secondary Mutational Resistance to Smoothed Antagonists. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 165-173.	1.9	77
98	Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. <i>Gastroenterology</i> , 2021, 160, 1373-1383.e6.	0.6	77
99	Treatment of Pancreatic Cancer Patient-Derived Xenograft Panel with Metabolic Inhibitors Reveals Efficacy of Phenformin. <i>Clinical Cancer Research</i> , 2017, 23, 5639-5647.	3.2	76
100	A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 5883-5894.	3.2	76
101	Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	72
102	Artificial Intelligence and Early Detection of Pancreatic Cancer. <i>Pancreas</i> , 2021, 50, 251-279.	0.5	71
103	The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma. <i>PLoS ONE</i> , 2017, 12, e0180181.	1.1	68
104	Global expression analysis of well-differentiated pancreatic endocrine neoplasms using oligonucleotide microarrays. <i>Clinical Cancer Research</i> , 2003, 9, 5988-95.	3.2	67
105	Heterogeneity and Targeting of Pancreatic Cancer Stem Cells. <i>Clinical Cancer Research</i> , 2012, 18, 4277-4284.	3.2	65
106	p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. <i>Cancer Cell</i> , 2019, 35, 204-220.e9.	7.7	62
107	Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. , 2020, 8, e000587.		62
108	Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer Microenvironment. <i>Gastroenterology</i> , 2022, 162, 2018-2031.	0.6	62

#	ARTICLE	IF	CITATIONS
109	GNASR201C Induces Pancreatic Cystic Neoplasms in Mice That Express Activated KRAS by Inhibiting YAP1 Signaling. <i>Gastroenterology</i> , 2018, 155, 1593-1607.e12.	0.6	61
110	Molecular Determinants of Retinoic Acid Sensitivity in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 280-289.	3.2	59
111	A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2015, 468, 525-532.	1.0	59
112	Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. <i>Cancer Cell</i> , 2018, 33, 752-769.e8.	7.7	58
113	Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA <i>CCAT2</i> induce myeloid malignancies via unique SNP-specific RNA mutations. <i>Genome Research</i> , 2018, 28, 432-447.	2.4	58
114	Pancreatic Cancer Database. <i>Cancer Biology and Therapy</i> , 2014, 15, 963-967.	1.5	57
115	Apurinic/Apyrimidinic Endonuclease/Redox Factor-1 (APE1/Ref-1) Redox Function Negatively Regulates NRF2. <i>Journal of Biological Chemistry</i> , 2015, 290, 3057-3068.	1.6	57
116	Relative Abundance of SARS-CoV-2 Entry Genes in the Enterocytes of the Lower Gastrointestinal Tract. <i>Genes</i> , 2020, 11, 645.	1.0	57
117	Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies. <i>Clinical Cancer Research</i> , 2021, 27, 5912-5921.	3.2	57
118	Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1532-1539.	1.9	54
119	Immunotherapy for Pancreatic Cancer: More Than Just a Gut Feeling. <i>Cancer Discovery</i> , 2018, 8, 386-388.	7.7	54
120	Heterogeneity of Pancreatic Cancer Metastases in a Single Patient Revealed by Quantitative Proteomics. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 2803-2811.	2.5	52
121	Altered hydroxymethylation is seen at regulatory regions in pancreatic cancer and regulates oncogenic pathways. <i>Genome Research</i> , 2017, 27, 1830-1842.	2.4	51
122	Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. <i>Cancer</i> , 2016, 122, 2671-2679.	2.0	49
123	SETD5-Coordinated Chromatin Reprogramming Regulates Adaptive Resistance to Targeted Pancreatic Cancer Therapy. <i>Cancer Cell</i> , 2020, 37, 834-849.e13.	7.7	48
124	Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy. <i>Pancreas</i> , 2017, 46, 1180-1187.	0.5	47
125	The number and ratio of positive lymph nodes affect pancreatic cancer patient survival after neoadjuvant therapy and pancreaticoduodenectomy. <i>Histopathology</i> , 2016, 68, 210-220.	1.6	46
126	YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma. <i>JCI Insight</i> , 2019, 4, .	2.3	46



#	ARTICLE	IF	CITATIONS
127	EMT: Matter of Life or Death?. Cell, 2016, 164, 840-842.	13.5	45
128	Proteins associated with pancreatic cancer survival in patients with resectable pancreatic ductal adenocarcinoma. Laboratory Investigation, 2015, 95, 43-55.	1.7	44
129	Direct Interactions With Cancer-Associated Fibroblasts Lead to Enhanced Pancreatic Cancer Stem Cell Function. Pancreas, 2019, 48, 329-334.	0.5	44
130	Roles and Regulations of TET Enzymes in Solid Tumors. Trends in Cancer, 2021, 7, 635-646.	3.8	43
131	Pancreatic Intraepithelial Neoplasia and Pancreatic Tumorigenesis: Of Mice and Men. Archives of Pathology and Laboratory Medicine, 2009, 133, 375-381.	1.2	43
132	Metabolic Imaging of Pancreatic Ductal Adenocarcinoma Detects Altered Choline Metabolism. Clinical Cancer Research, 2015, 21, 386-395.	3.2	42
133	4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. Clinical Cancer Research, 2017, 23, 7263-7275.	3.2	41
134	Single-cell RNA sequencing in pancreatic cancer. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 451-452.	8.2	40
135	Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer. British Journal of Cancer, 2016, 115, 442-453.	2.9	39
136	Subtyping Pancreatic Cancer. Cancer Cell, 2015, 28, 411-413.	7.7	38
137	Characterization and Comparison of GITR Expression in Solid Tumors. Clinical Cancer Research, 2019, 25, 6501-6510.	3.2	37
138	Pancreatitis and Pancreatic Cancer. Gastroenterology, 2019, 156, 1937-1940.	0.6	37
139	Obesity, Intrapancreatic Fatty Infiltration, and Pancreatic Cancer. Clinical Cancer Research, 2015, 21, 3369-3371.	3.2	36
140	A phase II study of vismodegib, a hedgehog (Hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA).. Journal of Clinical Oncology, 2014, 32, 257-257.	0.8	36
141	Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy. Cancer, 2018, 124, 1701-1709.	2.0	35
142	APOBEC3A drives deaminase domain-independent chromosomal instability to promote pancreatic cancer metastasis. Nature Cancer, 2021, 2, 1338-1356.	5.7	35
143	Suppression of stromal-derived Dickkopf-3 (DKK3) inhibits tumor progression and prolongs survival in pancreatic ductal adenocarcinoma. Science Translational Medicine, 2018, 10, .	5.8	33
144	Identification and Analysis of Precursors to Invasive Pancreatic Cancer. , 2005, 103, 001-014.		32

#	ARTICLE	IF	CITATIONS
145	Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer. <i>Physical Biology</i> , 2014, 11, 065002.	0.8	32
146	PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. <i>Nature Communications</i> , 2021, 12, 4626.	5.8	31
147	Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression. <i>Nature Biotechnology</i> , 2022, 40, 1624-1633.	9.4	31
148	Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater. <i>Annals of Surgical Oncology</i> , 2017, 24, 2031-2039.	0.7	30
149	A pipeline for rapidly generating genetically engineered mouse models of pancreatic cancer using in vivo CRISPR-Cas9-mediated somatic recombination. <i>Laboratory Investigation</i> , 2019, 99, 1233-1244.	1.7	30
150	p120 Catenin Suppresses Basal Epithelial Cell Extrusion in Invasive Pancreatic Neoplasia. <i>Cancer Research</i> , 2016, 76, 3351-3363.	0.4	29
151	A Functional Spatial Analysis Platform for Discovery of Immunological Interactions Predictive of Low-Grade to High-Grade Transition of Pancreatic Intraductal Papillary Mucinous Neoplasms. <i>Cancer Informatics</i> , 2018, 17, 117693511878288.	0.9	29
152	Epigenetic silencing of EYA2 in pancreatic adenocarcinomas promotes tumor growth. <i>Oncotarget</i> , 2014, 5, 2575-2587.	0.8	29
153	Isolation and mutational assessment of pancreatic cancer extracellular vesicles using a microfluidic platform. <i>Biomedical Microdevices</i> , 2020, 22, 23.	1.4	28
154	A new mouse model of pancreatic cancer: PTEN gets its Akt together. <i>Cancer Cell</i> , 2005, 8, 171-172.	7.7	27
155	Combining Hyperpolarized Real-Time Metabolic Imaging and NMR Spectroscopy To Identify Metabolic Biomarkers in Pancreatic Cancer. <i>Journal of Proteome Research</i> , 2019, 18, 2826-2834.	1.8	27
156	Selective EGLN Inhibition Enables Ablative Radiotherapy and Improves Survival in Unresectable Pancreatic Cancer. <i>Cancer Research</i> , 2019, 79, 2327-2338.	0.4	27
157	Characterisation of circulating tumour cell phenotypes identifies a partial-EMT sub-population for clinical stratification of pancreatic cancer. <i>British Journal of Cancer</i> , 2021, 124, 1970-1977.	2.9	26
158	Loss of Rnf43 Accelerates Kras-Mediated Neoplasia and Remodels the Tumor Immune Microenvironment in Pancreatic Adenocarcinoma. <i>Gastroenterology</i> , 2022, 162, 1303-1318.e18.	0.6	26
159	High Prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic Cancer. <i>Cancer Prevention Research</i> , 2018, 11, 679-686.	0.7	25
160	Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer. <i>Laboratory Investigation</i> , 2021, 101, 177-192.	1.7	25
161	PTHrP Drives Pancreatic Cancer Growth and Metastasis and Reveals a New Therapeutic Vulnerability. <i>Cancer Discovery</i> , 2021, 11, 1774-1791.	7.7	25
162	Reduced expression of argininosuccinate synthetase 1 has a negative prognostic impact in patients with pancreatic ductal adenocarcinoma. <i>PLoS ONE</i> , 2017, 12, e0171985.	1.1	25

#	ARTICLE	IF	CITATIONS
163	Disputed Paternity: The Uncertain Ancestry of Pancreatic Ductal Neoplasia. <i>Cancer Cell</i> , 2012, 22, 701-703.	7.7	24
164	Molecular envoys pave the way for pancreatic cancer to invade the liver. <i>Nature</i> , 2019, 567, 181-182.	13.7	24
165	Liquid biopsies in pancreatic cancer. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 869-878.	1.1	24
166	p120 Catenin is required for normal tubulogenesis but not epithelial integrity in developing mouse pancreas. <i>Developmental Biology</i> , 2015, 399, 41-53.	0.9	23
167	A Phase I Study of Dinaciclib in Combination With MK2206 in Patients With Advanced Pancreatic Cancer. <i>Clinical and Translational Science</i> , 2020, 13, 1178-1188.	1.5	23
168	Loss of ARID1A Promotes Epithelial-Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress. <i>Cancer Research</i> , 2021, 81, 332-343.	0.4	22
169	Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer. <i>Cancer Discovery</i> , 2022, 12, 2330-2349.	7.7	22
170	Dynamic changes during the treatment of pancreatic cancer. <i>Oncotarget</i> , 2018, 9, 14764-14790.	0.8	21
171	Plasma-Derived Extracellular Vesicles Convey Protein Signatures That Reflect Pathophysiology in Lung and Pancreatic Adenocarcinomas. <i>Cancers</i> , 2020, 12, 1147.	1.7	20
172	Defining the Comprehensive Genomic Landscapes of Pancreatic Ductal Adenocarcinoma Using Real-World Endoscopic Aspiration Samples. <i>Clinical Cancer Research</i> , 2021, 27, 1082-1093.	3.2	20
173	Prognostic and Functional Significance of MAP4K5 in Pancreatic Cancer. <i>PLoS ONE</i> , 2016, 11, e0152300.	1.1	20
174	PARP inhibition offers opportunities in pancreatic cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 595-596.	12.5	19
175	Of scientists and tweets. <i>Nature Reviews Cancer</i> , 2019, 19, 479-480.	12.8	19
176	Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-15.	1.5	19
177	The emerging roles of F-box proteins in pancreatic tumorigenesis. <i>Seminars in Cancer Biology</i> , 2016, 36, 88-94.	4.3	18
178	Overexpression of <i>ankyrin1</i> promotes pancreatic cancer cell growth. <i>Oncotarget</i> , 2016, 7, 34977-34987.	0.8	18
179	Recent advances in genomic profiling of adenocarcinoma of the pancreas. <i>Journal of Pathology</i> , 2017, 243, 271-272.	2.1	17
180	A microfluidic device for label-free isolation of tumor cell clusters from unprocessed blood samples. <i>Biomicrofluidics</i> , 2019, 13, 044111.	1.2	17

#	ARTICLE	IF	CITATIONS
181	Cost-effectiveness of consensus guideline based management of pancreatic cysts: The sensitivity and specificity required for guidelines to be cost-effective. <i>Surgery</i> , 2020, 168, 601-609.	1.0	17
182	Plasma miRNA Biomarkers in Limited Volume Samples for Detection of Early-stage Pancreatic Cancer. <i>Cancer Prevention Research</i> , 2021, 14, 729-740.	0.7	16
183	Overexpression of CD73 in pancreatic ductal adenocarcinoma is associated with immunosuppressive tumor microenvironment and poor survival. <i>Pancreatology</i> , 2021, 21, 942-949.	0.5	16
184	Loss of HNF6 expression correlates with human pancreatic cancer progression. <i>Laboratory Investigation</i> , 2014, 94, 517-527.	1.7	15
185	Pancreatic Cancer Genomics 2.0: Profiling Metastases. <i>Cancer Cell</i> , 2017, 31, 309-310.	7.7	15
186	Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers. <i>Nature Communications</i> , 2020, 11, 5332.	5.8	15
187	CES2 sustains HNF4 $\beta$ expression to promote pancreatic adenocarcinoma progression through an epoxide hydrolase-dependent regulatory loop. <i>Molecular Metabolism</i> , 2022, 56, 101426.	3.0	14
188	Early Detection of Pancreatic Intraepithelial Neoplasias (PanINs) in Transgenic Mouse Model by Hyperpolarized $^{13}\text{C}$ Metabolic Magnetic Resonance Spectroscopy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3722.	1.8	13
189	Occult polyclonality of preclinical pancreatic cancer models drives in vitro evolution. <i>Nature Communications</i> , 2022, 13, .	5.8	13
190	Paradoxical Role of AT-rich Interactive Domain 1A in Restraining Pancreatic Carcinogenesis. <i>Cancers</i> , 2020, 12, 2695.	1.7	12
191	Ezrin Promotes Stem Cell Properties in Pancreatic Ductal Adenocarcinoma. <i>Molecular Cancer Research</i> , 2019, 17, 929-936.	1.5	11
192	Predictive Modeling for Voxel-Based Quantification of Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma (PDAC): A Multi-Institutional Study. <i>Cancers</i> , 2020, 12, 3656.	1.7	11
193	Hematopoietic progenitor kinase 1 down-regulates the oncogenic receptor tyrosine kinase AXL in pancreatic cancer. <i>Journal of Biological Chemistry</i> , 2020, 295, 2348-2358.	1.6	11
194	Phase I study of mesenchymal stem cell (MSC)-derived exosomes with KRAS <sup>G12D</sup> siRNA in patients with metastatic pancreatic cancer harboring a KRAS <sup>G12D</sup> mutation.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS633-TPS633.	0.8	11
195	Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. , 2022, 10, e003082.		11
196	Diminished Immune Surveillance during Histologic Progression of Intraductal Papillary Mucinous Neoplasms Offers a Therapeutic Opportunity for Cancer Interception. <i>Clinical Cancer Research</i> , 2022, 28, 1938-1947.	3.2	11
197	Detection of Pancreatic Cancer-Induced Cachexia Using a Fluorescent Myoblast Reporter System and Analysis of Metabolite Abundance. <i>Cancer Research</i> , 2016, 76, 1441-1450.	0.4	10
198	Brain metabolites in cholinergic and glutamatergic pathways are altered by pancreatic cancer cachexia. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 1487-1500.	2.9	10

#	ARTICLE	IF	CITATIONS
199	Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma Exhibit Differential Growth and Metabolic Patterns in the Pre-Diagnostic Period: Implications for Early Detection. <i>Frontiers in Oncology</i> , 2020, 10, 596931.	1.3	10
200	Imaging Axl expression in pancreatic and prostate cancer xenografts. <i>Biochemical and Biophysical Research Communications</i> , 2014, 443, 635-640.	1.0	9
201	CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diabetes. <i>JCO Precision Oncology</i> , 2020, 4, 426-436.	1.5	9
202	Pancreatic Safety of Newer Incretin-Based Therapies: Are the "-tides" Finally Turning?. <i>Diabetes</i> , 2014, 63, 2219-2221.	0.3	8
203	Molecular and Genetic Basis of Pancreatic Carcinogenesis. <i>Surgical Oncology Clinics of North America</i> , 2016, 25, 227-238.	0.6	8
204	First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 619-627.	0.7	8
205	Upfront molecular profiling of pancreatic cancer patients "An idea whose time has come. <i>Pancreatology</i> , 2020, 20, 391-393.	0.5	8
206	Hear Pancreatic Cancer Stem Cells ROR. <i>Cell</i> , 2019, 177, 516-518.	13.5	7
207	Early detection of pancreatic cancer: current state and future opportunities. <i>Current Opinion in Gastroenterology</i> , 2021, 37, 532-538.	1.0	6
208	Quality of life impact of EUS in patients at risk for developing pancreatic cancer. <i>Endoscopic Ultrasound</i> , 2020, 9, 53.	0.6	6
209	Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective. <i>Cancer and Metastasis Reviews</i> , 2022, 41, 147-172.	2.7	6
210	Adequacy evaluation and use of pancreatic adenocarcinoma specimens for next-generation sequencing acquired by endoscopic ultrasound-guided FNA and FNB. <i>Cancer Cytopathology</i> , 2022, 130, 275-283.	1.4	6
211	It's a SMAD/SMAD World. <i>Cell</i> , 2015, 161, 1245-1246.	13.5	5
212	Hyperpolarized Magnetic Resonance and Artificial Intelligence: Frontiers of Imaging in Pancreatic Cancer. <i>JMIR Medical Informatics</i> , 2021, 9, e26601.	1.3	5
213	Twitter Conversations About Pancreatic Cancer by Health Care Providers and the General Public: Thematic Analysis. <i>JMIR Cancer</i> , 2022, 8, e31388.	0.9	5
214	A New Scalpel for the Treatment of Pancreatic Cancer: Targeting Stromal-Derived STAT3 Signaling. <i>Gastroenterology</i> , 2015, 149, 1685-1688.	0.6	4
215	KrÄppel-Like Factor 4 Promotes Pancreatic Acinar-to-Ductal Metaplasia and Tumor Initiation. <i>Pancreas</i> , 2017, 46, 139-142.	0.5	4
216	Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma. <i>Pancreatology</i> , 2021, 21, 200-207.	0.5	4

#	ARTICLE	IF	CITATIONS
217	HIF2 Regulates Intestinal Wnt5a Expression. <i>Frontiers in Oncology</i> , 2021, 11, 769385.	1.3	4
218	Extrahepatic Biliary Atresia Demonstrates Abnormal Persistence of HES1 Protein in Neonatal Biliary Epithelium: An Immunohistochemical Study. <i>Pediatric and Developmental Pathology</i> , 2006, 9, 98-102.	0.5	3
219	GRP78 expression and prognostic significance in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant therapy versus surgery first. <i>Pancreatology</i> , 2021, 21, 1378-1385.	0.5	3
220	Oncogenic KRAS Requires Complete Loss of BAP1 Function for Development of Murine Intrahepatic Cholangiocarcinoma. <i>Cancers</i> , 2021, 13, 5709.	1.7	3
221	Precision Promise (PrP): An adaptive, multi-arm registration trial in metastatic pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4188-TPS4188.	0.8	3
222	Bringing Pathobiology into Focus. <i>Laboratory Investigation</i> , 2006, 86, 632-632.	1.7	2
223	Introduction of #PancChat: A novel Twitter platform to inform and engage the pancreatic cancer community.. <i>Journal of Clinical Oncology</i> , 2018, 36, 242-242.	0.8	2
224	Heterogeneity of Tumor Exosomes – Role in Precision Medicine. , 2018, , 59-67.		1
225	Membrane-bound MMP-14 protease-activatable adeno-associated viral vectors for gene delivery to pancreatic tumors. <i>Gene Therapy</i> , 2021, , .	2.3	1
226	A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 925-935.	0.6	0
227	Improvement in lung health in PCD. <i>Journal of Paediatrics and Child Health</i> , 2021, , .	0.4	0
228	Implementation of a Video-based Remote Germline Testing for Individuals With Pancreatic Ductal Adenocarcinoma. <i>Gastroenterology</i> , 2022, 163, 316-318.e1.	0.6	0